Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O(6)-methylguanine DNA methyltransferase as a biomarker for response

Recent advances in the treatment of neuroendocrine tumors (NET), including the combination regimen of capecitabine and temozolomide (CAPTEM), have mostly focused on grade 1 and 2 pancreatic neuroendocrine tumors (pNET). We undertook a retrospective review of 38 patients with advanced NET treated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Owen, Dwight H., Alexander, Andrew J., Konda, Bhavana, Wei, Lai, Hemminger, Jessica A., Schmidt, Carl R., Abdel-Misih, Sherif R.Z., Dillhoff, Mary E., Sipos, Jennifer A., Kirschner, Lawrence S., Shah, Manisha H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732786/
https://www.ncbi.nlm.nih.gov/pubmed/29262620
http://dx.doi.org/10.18632/oncotarget.22001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732786/
https://www.ncbi.nlm.nih.gov/pubmed/29262620
http://dx.doi.org/10.18632/oncotarget.22001

Ejemplares similares